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Several enveloped viruses exploit host pathways,
such as the cellular endosomal sorting complex
required for transport (ESCRT) machinery, for their
assembly and release. The influenza A virus (IAV) ma-
trix protein binds to the ESCRT-I complex, although
the involvement of early ESCRT proteins such as
Tsg101 in IAV trafficking remain to be established.
We find that Tsg101 can facilitate IAV trafficking,
but this is effectively restricted by the interferon
(IFN)-stimulated protein ISG15. Cytosol from type I
IFN-treated cells abolished IAV hemagglutinin (HA)
transport to the cell surface in infected semi-intact
cells. This inhibition required Tsg101 and could be
relieved with deISGylases. Tsg101 is itself ISGylated
in IFN-treated cells. Upon infection, intact Tsg101-
deficient cells obtained by CRISPR-Cas9 genome
editing were defective in the surface display of HA
and for infectious virion release. These data support
the IFN-induced generation of a Tsg101- and ISG15-
dependent checkpoint in the secretory pathway that
compromises influenza virus release.
INTRODUCTION
The assembly and release of enveloped viruses is a multistep
process that requires host factors and is often hijacked by the
virus in order to execute membrane remodeling and budding.
The most well-characterized are retroviruses, which exploit the
cellular endosomal sorting complex required for transport
(ESCRT) machinery for budding (Martin-Serrano and Neil,
2011). The matrix protein of many such viruses contains a late-
domain sequence (PTAP or L domain) that binds to components
of theESCRTmachinery typically involved in the formationof ves-
icles into multivesicular bodies. Influenza viruses, on the other
hand, are believed to have evolved an ESCRT-independent
mode of budding, but the exact mechanism of influenza virus as-
sembly and budding is not clear. The consensus is that the coat510 Cell Host & Microbe 14, 510–521, November 13, 2013 ª2013 Elsproteins initiate the process. Hemagglutinin (HA) and neuramini-
dase associate with the virus matrix protein M1 at lipid microdo-
mains followedby the recruitment ofM2—an ionchannel capable
of alteringmembranecurvature (Rossmanet al., 2010).Mutations
introduced into the amphipathic helix of M2 abolish membrane
scission and virus release (Rossman and Lamb, 2011; Rossman
et al., 2010). Although influenza lacks a conventional L domain,
thematrix protein M1 binds to the ESCRT-I complex, suggesting
a possible role in assembly (Bruce et al., 2009). Budding of fila-
mentous and nonfilamentous influenza A requires neither VPS4
nor VPS28 (Bruce et al., 2009). However, the involvement of early
ESCRT proteins such as Tsg101 in intracellular trafficking of IAV
remains to be demonstrated directly.
Host cells impose restrictions on various steps in the virus
life cycle, including entry, replication, assembly, and release.
Antiviral mechanisms are launched by the induction of type I
interferon (IFN-I) in the infected cell. ISG15 is one of the most
abundantly expressed genes upon IFN-I signaling, and it has
general antiviral effects (Skaug and Chen, 2010; Zhao et al.,
2010). Retrovirus release is blocked upon IFN-I treatment or by
exogenous expression of ISG15 (Seo and Leis, 2012; Zhao
et al., 2013). ISG15 knockout mice (ISG15/) show increased
susceptibility to a number of virus infections, including influenza
(Hsiang et al., 2009). The expression of ISG15 blocks the budding
of a number of viruses through the conjugation of ESCRTcompo-
nents that are employed during virus infections. For example, the
budding of Ebola virus-like-particle is blocked by ISG15 through
the inhibition of Nedd4 ligase activity; HIV-1 budding is impaired
upon IFN induction because of a loss of Tsg101 binding to the
HIV Gag protein. Although the nonstructural protein 1 (NS1) of
influenza B virus directly binds to and antagonizes the activity
of ISG15, this is not the case for influenza A virus (Zhao et al.,
2013; Yuan and Krug, 2001; Hsiang et al., 2009).
Here, we use a biochemical assay based on the use of per-
fringolysin O (PFO)-perforated semi-intact cells to study flu
biogenesis. This preparation faithfully recapitulates intracellular
glycoprotein trafficking and virus release. PFO is a cholesterol-
binding, pore-forming toxin that selectively perforates the
plasma membrane while leaving intracellular organelles intact.
Thus, we can manipulate the composition of the cytoplasm as
well as deliver otherwise cell-impermeable reagents such as
the nonhydrolysable GTP analog GTPgS in order to determineevier Inc.
Figure 1. Trafficking of IAV in Semi-Intact
Cells Requires Added Cytosol
1 3 106 MDCK cells were infected with influenza
A/WSN/33 at a multiplicity of infection (MOI) of
0.5 for 5 hr and radiolabeled with [35S]cysteine/
methionine. Cells were left intact or permeabilized
with 100 nM PFO, supplemented with concen-
trated MDCK cytosol, and chased for 30 and
60 min. At each time point, pellet and supernatant
fractions were separated by centrifugation.
(A and B) Experimental setup.
(C) Top: pellet fractions were lysed and immuno-
precipitated with anti-HA IgG2b on protein G
beads. Pulse-chase experiments on intact cells
(lanes 1–3). Semi-intact cells supplemented with
MDCK cytosol (lanes 7–9). Absence of exogenous
cytosol or addition of GTPgS arrests HA in the ER
(lanes 10–12). Bottom: EndoH digested HA in the
pellet fractions.
(D) Supernatant fractions from intact or per-
meabilized cells were treated with chicken eryth-
rocytes in order to isolate intact virions. Release of
virus particles occurred in intact cells (lanes 1–3)
and semi-intact cells supplemented with cytosol
(lanes 7–9).
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Exogenous cytosol from various sources can be delivered to
these semi-intact cells through a mild osmotic shock. We previ-
ously used this preparation to measure ATP-dependent trans-
port of misfolded glycoproteins from the endoplasmic reticulum
(ER) to the cytosol as part of a protein quality control system
(Ernst et al., 2011; Sanyal et al., 2012). Now, we have extended
this approach to understand intracellular protein trafficking
routes upon IFN induction during influenza virus infection and
to identify cytosolic components relevant for the process. We
show that semi-intact cells support virus assembly and release
with kinetics comparable to those of intact cells. We identified
Tsg101 as a component essential for the post-Golgi trafficking
of HA to the plasma membrane (PM) prior to the budding of
the virus and find that Tsg101 is ISGylated upon the exposure
of cells to IFN, providing a plausible link between IFN exposure
and interference with glycoprotein trafficking. Cas9-CRISPR-
mediated inactivation of Tsg101 yielded cells refractory to
infection, possibly because of defects in virus entry, thus under-
scoring the advantage of using semi-intact cells to resolve virus
entry, assembly, and release processes. Both the use of semi-
intact cells and the generation of a knockout cell line establish
the involvement of Tsg101 upon IFN induction and influenza
infection. Endogenous glycoprotein transport acquires a pro-
nounced dependency on Tsg101 in IFN-I-treated cells, which
is negatively regulated by ISG15 and exploited by IAV during
infection.
RESULTS
Trafficking of IAV in Semi-Intact Cells Requires
Exogenous Cytosol
To demonstrate trafficking and budding of IAV in PFO-permeabi-
lized cells, we infected Madin-Darby canine kidney (MDCK) cells
with influenza A/WSN/33 for 5 hr. Then, cells were pulse labeledCell Host &with [35S]cysteine/methionine for 10 min, treated with PFO at
0C, washed briefly in order to remove excess PFO, and trans-
ferred to 37C in order to initiate permeabilization of the PM.
This approach allowed us to track the fate of the wave of only
newly synthesized viral proteins while ignoring the contribu-
tion of unlabeled virus particles poised for release at the time
of perforation. The same strategy of cell permeabilization, per-
formed in a small volume in order to minimize dilution, yielded
concentrated cytosol (Figure 1A). We incubated PFO-treated
cells with cytosol from MDCK cells at 37C for the indicated
times. At each time point, the supernatant and the pellet fractions
were separated by centrifugation. Pellet fractions were lysed in
NP40-containing lysis buffer and treated with anti-HA antibodies
immobilized on protein G beads in order to recover HA. In order
to isolate intact virions released from the PFO-treated cells,
supernatants were adsorbed onto chicken erythrocytes, which
capture viral particles via the sialic acids on the erythrocytes
(Figure 1B). Then, the material was visualized by SDS-PAGE
and autoradiography.
First, wemeasured intracellular trafficking of HA from the ER to
the Golgi and from there to the PM in semi-intact cells by moni-
toring the maturation of N-linked glycans on HA (Figure 1C).
The ER-resident, high-mannose form of HA can be distinguished
from its Golgi counterpart by its distinct mobility on SDS-PAGE
and by the sensitivity of the former to treatment with endoglyco-
sidase H (EndoH) (Figure 1C, bottom). The inclusion of trypsin in
the incubation medium allowed an assessment of the appear-
ance of HA at the cell surface through formation of HA1 and
HA2—the trypsin-cleavage products of HA0. Access of trypsin
to the cytosol cannot result in the conversion of intracellular
HA0 into HA1 and HA2 because the cleavage site in HA0 is lume-
nally disposed and, therefore, not accessible to added protease
even when it enters perforated cells. In the absence of added
cytosol, intracellular transport of HA ceased (Figure 1C). Kinetics
of intracellular transport and surface display of HA in semi-intactMicrobe 14, 510–521, November 13, 2013 ª2013 Elsevier Inc. 511
Figure 2. Cytosol from IAV-Infected and IFN-I-Treated Cells Have
Distinct Effects on Virus Release from Semi-Intact Cells
13 106 MDCK cells were infected with influenza A/WSN/33 at an MOI of0.5
for 5 hr and radiolabeled with [35S]cysteine/methionine. Permeabilized cells
were supplemented with (1) concentrated MDCK cytosol, (2) MDCK cytosol
from IAV-infected cells, and (3) MDCK cytosol treated with IFN-I and chased
for 30 and 60 min. At each time point, pellet and supernatant fractions were
separated by centrifugation.
(A) Pellet fractions were lysed and immunoprecipitated with anti-HA IgG2b on
protein G beads. Control cytosol (lanes 1–3) and cytosol from IAV-infected
MDCK cells (lanes 4–6). Cytosol from IFN-treated MDCK cells (lanes 7–9) does
not support HA transport from the Golgi to the PM. Cytosol supplemented with
GTPgS (lanes 10–12).
(B) Supernatant fractions from permeabilized cells were treated with chicken
erythrocytes in order to isolate intact virions. Release of virus particles with
control cytosol (lanes 1–3) and cytosol from IAV-infected cells (lanes 4–6) with
IFN-treated cytosol (lanes 7–9) or GTPgS-supplemented cytosol (lanes 10–12).
See also Figure S1.
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cells, as measured by conversion of HA’s high-mannose glycans
to the complex type and the appearance of HA1 and HA2. The
inclusion of GTPgS abolished transport from the ER to Golgi,
which was anticipated because of its inhibition of coat protein II
mediated vesicular transport (Lee andMiller, 2007). The inclusion
of GTPgS is an important control that establishes quantitative
permeabilization; residual intact cells would have supported
HA maturation. In parallel with transport and surface arrival of
HA, semi-intact cells supplemented with concentrated MDCK
cytosol released intact virus or virus-like particles recovered by
adsorption to chicken red blood cells (Figure 1D). The omission
of cytosol or inclusion of GTPgS blocked the release of virus par-
ticles. Thus, semi-intact cells support virus assembly and release512 Cell Host & Microbe 14, 510–521, November 13, 2013 ª2013 Elswhen supplemented with cytosol from a compatible exogenous
source and do so at rates comparable to those seen in intact
cells. The composition of the released particles—as assessed
by SDS-PAGE and autoradiography—is indistinguishable for
intact and cytosol-supplemented semi-intact cells.
Cytosol from IAV-Infected and IFN-I-Treated Cells Have
Distinct Effects on Virus Release
We hypothesized that IAV infection induces host factors in the
cytosol that modulate virus assembly and budding. Mammalian
cells respond to virus infection by producing IFN-I, which, in turn,
induces the expression of host factors with antiviral properties, a
process that takes several hours. Viruses have evolved counter-
measures for inducing host genes that facilitate virus trafficking
and release either directly or by the modification of the existing
sets of proteins while downregulating the expression of genes
that compromise infection. To recapitulate such a physiological
cytosolic environment, we used two different sources of cytosol:
we extracted cytosol from MDCK cells that had either been
infected with IAV or treated with IFN-I. Cytosol obtained from
IAV-infected cells soon after infection would contain host pro-
teins that assist in virus assembly and release. On the other
hand, cytosol extracted from cells treated with IFN-I would be
enriched in host factors that contribute to an antiviral milieu.
We supplied these extracts to IAV-infected radiolabeled cells,
permeabilized using PFO as described above. Cytosol from un-
infected MDCK cells was used as a control (Figure 2A). Neither
the abundance of HA nor the kinetics of trafficking from the ER
to the Golgi were affected by the provision of different cytosol
preparations, relative to control cells. However, the arrival of
HA at the cell surface, as measured by the cleavage of HA0
with the concomitant appearance of HA1 and HA2, was impaired
by cytosol from IFN-treated cells (Figure 2A). We observed no
impairment in particle release into the supernatants from semi-
intact cells supplied with cytosol from IAV-infected cells (Fig-
ure 2B). The provision of cytosol from IFN-treated cells likewise
abolished particle release. Therefore, cytosol from IFN-treated
cells must contain proteins that prevent the arrival of HA at the
cell surface and its subsequent incorporation into virions or
must lack proteins necessary for this to occur. This block occurs
after the acquisition of complex-type glycans. The fraction of
viral proteins that appear in released virions is too low to result
in a measurable accumulation of intracellular HA upon the inhibi-
tion of virus release. The release of virions seen upon supple-
mentation with cytosol from IAV-infected cells appears to be a
consequence of NS1-mediated inhibition of a restriction factor
(Figure S1 available online).
ISG15 Inhibits a Late Step in IAV Glycoprotein Transport
and Blocks Virus Release
ISG15 is an abundantly expressed gene induced immediately
upon exposure to IFN-I. We hypothesized that the observed
blockade in HA transport to the cell surface in IFN-I-exposed
cytosolic extracts was due to the ISGylation of host compo-
nents that, in their unmodified form, facilitate virus trafficking.
Therefore, we expressed Ubp43 (a specific deISGylase) (Mala-
khov et al., 2002) or CCHFVL-Otu (L protein of Crimean-Congo
hemorrhagic fever virus containing an ovarian tumor domain
that antagonizes ISG15 activity) (Frias-Staheli et al., 2007) inevier Inc.
Figure 3. ISG15 Blocks a Late Step in Glycoprotein Transport
13 106 MDCK cells were infected with influenza A/WSN/33 at an MOI of 0.5 for 5 hr and radiolabeled with [35S]cysteine/methionine. Permeabilized cells were
supplemented with (1) concentrated MDCK cytosol, (2) cytosol treated with IFN-I mixed with HEK 293T cytosol expressing an empty vector control, (3) IFN-I-
treated cytosol mixed with Ubp43 expressed in HEK 293T cells, (4) IFN-I-treated cytosol mixed with CCHFVL-Otu (OtuL) expressed in HEK 293T cells, and (5)
IFN-I-treated cytosol mixed with catalytically dead variant of CCHFVL-Otu (mOtuL) expressed in HEK 293T cells and chased for 30 and 60 min.
(A) Pellet fractionswere lysed and immunoprecipitated with anti-HA IgG2b on protein G beads. Control cytosol (lanes 1–3), IFN-treated cytosol with empty control
vector (lanes 4–6), and cytosol from IFN-treated cells mixed with Ubp43 (lanes 7–9), CCHFVL-Otu (lanes 10–12), or mutant CCHFVL-Otu (lanes 13–15).
(B) Supernatant fractions from permeabilized cells were treated with chicken erythrocytes in order to isolate intact virions. Virus particles released with control
cytosol (lanes 1–3) or that from IFN-I treatment mixed with either Ubp43 (lanes 7–9) or CCHFVL-Otu (lanes 10–12). A block in release occurred with IFN-treated
cytosol mixed with either control empty vector (lanes 4–6) or mutant CCHFVL-Otu (lanes 12–15).
(C) Intact A549 cells either mock-treated or treated with IFN-I for 8 hr (top left) were infected with HA-Srt virus (A/WSN/33 with a sortaggable HA) for 5 hr through a
brief acid shock at pH 5, pulse labeled with [35S]cysteine/methionine, and chased for the indicated time intervals. HA at the cell surface was biotinylated with
sortase A and GGGK-biotin and isolated on NeutrAvidin beads, whereas total HA in the cell was immunoprecipitated on anti-HA antibodies. A549 cells trans-
fected with either empty control vector or Ubp43 were IFN-I treated and infected with HA-Srt as above (top right). Surface HA was biotinylated, and total HA was
immunoprecipitated on anti-HA antibodies. Bottom: the amount of HA reaching the cell surface was quantitated through densitometric analysis of the ratio of
biotinylated HA to the total (intracellular + surface) HA ([HAbiotin/HAtotal] 3 100). Error bars are from three independent experiments.
(D) Radiolabeled particles released into the media from intact A549 cells were adsorbed onto chicken erythrocytes and resolved by SDS-PAGE.
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cytosol fractions by PFO treatment. Cytosol from IFN-I-treated
cells was mixed with that of either Ubp43 or CCHFVL-Otu-con-
taining cytosol in a 1:1 ratio and supplied to semi-intact cells in
order to measure HA transport and virus production. An inac-
tive mutant of CCHFVL-Otu served as a control. To control
for the dilution of factors essential for transport, we mixed
cytosol from IFN-treated cells with that of HEK 293T cells ex-
pressing an empty vector in a 1:1 ratio. The provision of this
mixture inhibited the arrival of HA at the cell surface, indicating
no loss of activity of the IFN-induced factors upon 2-fold dilu-
tion (Figure 3A). For cytosol from IFN-I-treated cells supple-Cell Host &mented with either Ubp43 or CCHFVL-Otu, the transport of
HA to the cell surface was restored, as judged from the appear-
ance of HA1 and HA2. The catalytically inactive mutant of
CCHFVL-Otu failed to relieve the inhibition observed upon the
supply of cytosol from IFN-I-treated cells. These observations
were corroborated by measuring the release of virus particles
(Figure 3B). Block in virus release imposed upon IFN-I treat-
ment was restored in samples incubated with either Ubp43 or
CCHFVL-Otu, but not with inactive CCHFVL-Otu. Therefore,
ISG15 must modify either a viral or host protein that inhibits a
late step in the assembly of progeny virions and their subse-
quent release from cells.Microbe 14, 510–521, November 13, 2013 ª2013 Elsevier Inc. 513
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lung epithelial cell line A549. We introduced either a control vec-
tor or an Ubp43 construct into these cells and treated them with
IFN-I for 8 hr. Given that IFN-I treatment renders cells refractory
to infection, we forced the fusion of virus (HA-Srt, multiplicity of
infection of 1) at the plasma membrane by a brief exposure to
pH 5.5 in order to deliver viral ribonucleoproteins (vRNPs) to
the cytosol (White et al., 1981). The HA-Srt virus generated
from A/WSN/33 contains an LPETG motif on its HA that can be
selectively biotinylated with sortase A (Popp et al., 2012). Upon
incubation (4 hr) in order to allow the synthesis of viral proteins,
we performed a pulse-chase experiment. At each time point,
cell-surface-displayed HA was biotinylated with sortase A and
isolated on NeutrAvidin beads, whereas total HA was immuno-
precipitated with anti-HA antibodies. We observed a block in
the arrival of HA at the cell surface in IFN-I-treated cells that
was restored in transfectants that express Ubp43 (Figure 3C).
Supernatants released from these cells were adsorbed onto
chicken erythrocytes and resolved by SDS-PAGE (Figure 3D).
As observed with the surface appearance of HA, the release of
intact virions was blocked upon IFN-I treatment and restored
by the expression of Ubp43. The presence of radiolabeled M1
at the later time points in IFN-I-treated cells is most likely
attributable to nonspecific adsorption due to the release of viral
components by dying cells.
HA Transport to the Cell Surface Is Vps4 Independent
but Tsg101 Dependent
An obvious target of ISGylation is the ESCRT machinery.
Components of the ESCRT machinery, such as HIV-I, can be
ISGylated and have been implicated in the budding of retrovi-
ruses (Martin-Serrano et al., 2001; Okumura et al., 2006). For
the biogenesis of IAV, the involvement of the ESCRT com-
plex was considered unlikely, given that a dominant-negative
version of Vps4, an effector protein on which the ESCRT com-
plexes converge, did not affect virus budding (Watanabe and
Lamb, 2010). Instead, IAV budding is facilitated by M2, an ion
channel equipped with an amphipathic helix that can alter
membrane curvature (Chen et al., 2008; Rossman et al.,
2010). We prepared cytosol from MDCK cells by permeabiliza-
tion with PFO and depleted it of either Vps4 or Tsg101 (Fig-
ure 4A). Only trace amounts of Vps4 or Tsg101 remained, as
verified by immunoblotting. Levels of GAPDH remained
unchanged, verifying that depletion was specific. Cytosol that
either contained Vps4 or had been depleted of Vps4 was
applied to semi-intact cells infected with IAV in order to mea-
sure the trafficking of HA. Both Vps4-replete and Vps4-depleted
cytosol supported the transport of HA to the cell surface
(Figure 4B).
Tsg101 is a component of the ESCRT-I complex involved in
the intracellular transport and assembly of a number of viruses
such as HIV and Ebola (Martin-Serrano et al., 2001). To test
the involvement of Tsg101 in transport and externalization of
HA, we immunodepleted cytosol with anti-Tsg101 as described
for Vps4 (Figure 4C). We delivered control and Tsg101-deficient
cytosol to [35S]cysteine/methionine semi-intact cells infected
with IAV. Samples that received mock-depleted cytosol dis-
played unaltered kinetics of HA transport to the cell surface.
Tsg101-depleted cytosol supported ER-to-Golgi transport, but514 Cell Host & Microbe 14, 510–521, November 13, 2013 ª2013 Elsnot post-Golgi traffic of HA to the PM. Our results indicate that
Tsg101 is required for HA to reach the cell surface from the Golgi
network.
Next, we determined whether the Tsg101 dependence
observed in infected cells also applies to cytosol from cells
treated with IFN-I. Samples were supplemented with cytosol
transduced with Ubp43 in order to relieve the transport of
HA to the cell surface and tested in the presence or absence
of Tsg101. Samples that received mock-depleted cytosol
from IFN-I-treated cells supplemented with Ubp43 supported
post-Golgi HA transport, whereas Tsg101-deficient extracts
failed to do so regardless of the presence of Ubp43. GTPgS-
supplemented cytosol was used as control for permeabili-
zation. We conclude that intracellular traffic of HA relies on
a Tsg101-dependent step and is sensitive to ISGylation.
We examined the modification status of Tsg101 in transfec-
tants that express HA-tagged ISG15. Covalent modification of
Tsg101 with ISG15 was only observed in cells exposed to
IFN-I, required for induction of the ISG15 conjugation appa-
ratus, and reversed by cotransfection with the deISGylase
Ubp43 (Figure 4D).
IFN-I Imposes a Block in the Transport of HA to the Cell
Surface in Cas9-CRISPR-Mediated Tsg101 Knockout
Cells
We generated Tsg101-deficient A549 cells using the Cas9-
CRISPR method (Cong et al., 2013; Hwang et al., 2013; Mali
et al., 2013) as well as siRNA-mediated knockdowns (data not
shown). Although the ablation of Tsg101 is embryonically lethal
(Wagner et al., 2003), we obtained several clones of Tsg101/
A549 cells. These displayed reduced growth rates in compari-
son to wild-type (WT) cells but showed no gross morphological
defects, as seen by light microscopy. We isolated five clones
for which the deletion of Tsg101 was verified by immunoblotting
of cell lysates (Figure 5A). Tsg101/ cells showed no residual
Tsg101 and were refractory to infection by IAV, possibly
because of aberrations in the endocytic machinery imposed
by the Tsg101 deficiency. This observation underscores the
advantage of using semi-intact cells to separate entry and
assembly defects that are otherwise difficult to identify in
genome-wide screens applied to intact cells. In perforated cells,
the only distinction between the two experimental settings is the
presence or absence of Tsg101 from the delivered cytosol
during these short incubations, all intracellular organelles being
the same. Indeed, Tsg101 did not surface as a significant host
factor in any of the published RNAi screens (Brass et al.,
2009; Karlas et al., 2010; Shapira et al., 2009). To circumvent
the resistance of Tsg101/ cells to IAV infection through the
standard endosomal entry pathway, we resorted to low-pH
fusion of IAV in order to deliver vRNPs directly into the cytosol
and performed a pulse-chase experiment. At each time point,
surface-disposed HA was biotinylated with sortase A (Figure 5B,
top). Total intracellular HA was immunoprecipitated with anti-
HA antibodies (Figure 5B, bottom). We observed a complete
block in the arrival of HA at the cell surface in Tsg101/ cells,
confirming our findings with permeabilized cells (Figure 5B).
Likewise, the release of intact virions into the supernatant was
blocked in Tsg101/ cells, as observed by the absence of ra-
diolabeled virus particles (Figure 5D). The inhibition and releaseevier Inc.
Figure 4. HA Transport to the Cell Surface Is Vps4 Independent but Tsg101 Dependent
(A) Immunodepletions from MDCK cytosol performed with anti-Vps4 or anti-Tsg101 antibodies on protein A beads. Beads without antibodies were used as
control. Equivalent fractions of input and flowthrough were probed for Vps4 and Tsg101, respectively. GAPDHwas used as a loading control in order to verify that
depletion was specific.
(B) 1 3 106 MDCK cells were infected with influenza A/WSN/33 at an MOI of 0.5 for 5 hr and radiolabeled with [35S]cysteine/methionine. Cells were per-
meabilized with 100 nM PFO and supplemented with (1) concentrated MDCK cytosol, (2) MDCK cytosol treated with control beads, (3) cytosol depleted of Vps4,
and (4) cytosol supplemented with GTPgS and chased for 30 and 60 min. Control cytosol (lanes 1–3), cytosol containing Vps4 (lanes 4–6), and cytosol lacking
Vps4 (lanes 7–9). Cytosol supplemented with GTPgS (lanes 10–12).
(C) 1 3 106 MDCK cells were infected with influenza A/WSN/33 at an MOI of 0.5 for 5 hr and radiolabelled with [35S]cysteine/methionine. Permeabilized cells
were supplemented with (1) either mock-depleted or Tsg101-deficient concentrated MDCK cytosol, (2) MDCK cytosol treated with IFN-I, (3) either mock-
depleted or Tsg101-deficient MDCK cytosol treated with IFN-I mixed with Ubp43, and (5) cytosol supplemented with GTPgS and chased for 30 and 60 min.
Untreated cytosol containing Tsg101 (lanes 1–3), and cytosol lacking Tsg101 (lanes 4–6). Cytosol from IFN-treated cells treated with Ubp43 containing Tsg101
(lanes 10–12) or Tsg101-deficient cytosol (lanes 13–15). Cytosol supplemented with GTPgS (lanes 16–18). Autoradiograms are representative of at least three
independent experiments.
(D) HEK 293T cells were cotransfected with HA-ISG15 and either empty vector or Ubp43 deISGylase. Transfected cells were either untreated or treated with IFN-I
for 6 hr (100 U/ml) and lysed in NP-40. Lysates were immunoblotted with anti-HA antibodies. ISGylated products were immunoprecipitated with anti-HA and
probed with anti-Tsg101.
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plete, as confirmed by plaque assays (Figure 5C).
To identify the site at which the block in HA transport occurs,
we prepared control and Tsg101/ samples infected with IAV
at low pH for 5 hr. Fixed and permeabilized cells were stained
with TGN46 and anti-HA antibodies and examined by confocal
microscopy (Figure 5E). In WT A549 cells, HA was distributed
throughout the cell in a typical punctate pattern, whereas, in
Tsg101/ cells, HA was found in large accumulations that
colocalizedwith the TGN network. Our results in Tsg101/ cells,
combined with those of permeabilized cells, show that Tsg101
plays a critical role in the transport of HA from the TGN to the
plasma membrane.Cell Host &Specific Host Proteins Traffic via Tsg101-Dependent
Pathway upon IFN-I Induction
Tsg101-dependent transport of HA to the cell surface could be
either specific for IAV proteins or a more general consequence
of IFN-I exposure, which might affect other glycoproteins as
well. We asked whether the trafficking of at least a subset of
endogenous glycoproteins would display the same properties
as that of HA upon IFN-I induction. We took advantage of two
glycoprotein reporters, CD40L and transferrin receptor (TfR),
both of which were engineered to contain an LPETG tag, which
can be biotinylated on the surface of intact cells in a sortase
A-catalyzed reaction (Popp et al., 2007, 2009). We generated
MDCK cells that stably express either CD40L or TfR with anMicrobe 14, 510–521, November 13, 2013 ª2013 Elsevier Inc. 515
Figure 5. Cas9/CRISPR-Mediated Knockout of Tsg101 in A549 Cells
(A) Clonal isolates of A549 cells were immunoblotted for Tsg101 (+, control Tsg101-proficient cells; 1–9, different clonal isolates after limiting dilution).
(B) WT and Tsg101/ cells were infected with HA-Srt for 5 hr at an MOI of 1 through a brief acid shock at pH 5.0 followed by pulse labeling with [35S]cysteine/
methionine for 10min and chase for the indicated time intervals. At each time point, cell-surface HAwas biotinylated with sortase A andGGGK-biotin and isolated
on NeutrAvidin beads. The remaining intracellular HA was immunoprecipitated on anti-HA antibodies.
(C) Supernatants from infected (MOI = 1 at pH 5.0 for 4 hr)WT or Tsg101 knockout cells (three independent clones) were used to infectMDCK cells in 10-fold serial
dilutions. MDCK cells were plated and overlaid with agar. After 2 days of infection, cells were stained with biotin-conjugated anti-NP single variable domain of
heavy chain for visualization. Viral titers were quantitated from serial dilution of triplicates. Error bars represent mean ± SD.
(D) Radiolabeled particles released into the media from WT and Tsg101/ were adsorbed onto chicken erythrocytes and resolved by SDS-PAGE.
(E) WT and Tsg101/ A549 cells were infected with IAV (pH 5.0, MOI = 1) and incubated for 5 hr. Fixed and permeabilized cells were stained with anti-HA in
order to identify virus particles and anti-TGN46 in order to define the trans-Golgi network. Images were acquired with a PerkinElmer spinning disk confocal
microscope.
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Figure 6. Tsg101-Dependent Transport of Endogenous Host Proteins
(A) MDCK cells stably expressing either CD40L or TfR were treated with IFN-I for 8 hr, radiolabeled with [35S]cysteine/methionine for 15 min, and chased for the
indicated time intervals. At each time point, surface-displayed CD40L or TfR were biotinylated. Total CD40L or TfR were immunoprecipitated on anti-HA beads.
(B) TfR-expressing cells were radiolabeled, permeabilized, and supplemented with (1) either Tsg101-replete or Tsg101-deficient untreated MDCK cytosol or (2)
IFN-I-treated, Tsg101-replete, or Tsg101-deficient cytosol. At each time point, cell pellets were biotinylated with sortase A and GGGK-biotin and isolated on
NeutrAvidin beads. Total TfR was immunoprecipitated on anti-HA beads.
(C) MDCK cells expressing CD40L were either mock infected or infected with influenza A/WSN/33 virus at an MOI of 0.5 for 5 hr and radiolabeled. Permeabilized
cells were supplemented with Tsg101-replete or Tsg101-deficient cytosol. At each time point, pellets were treated with sortase A and GGGK-biotin for 1 hr on ice
and immunoprecipitated on NeutrAvidin beads (S, surface-displayed). Intracellular CD40L was immunoprecipitated on immobilized HA beads (T, total).
Uninfected cells (lanes 1–3 and 4–6). For flu-infected cells, transport of CD40L to the PM was abolished in the absence of Tsg101.
(D) CD40L-expressing cells were radiolabeled, permeabilized, and supplemented with (1) untreated MDCK cytosol; (2) IFN-I-treated, Tsg101-replete, or Tsg101-
deficient cytosol; and (3) either Tsg101-replete or Tsg101-deficient IFN-I-treated, Ubp43-expressing cytosol. At each time point, pellets from these semi-intact
cells were treated with sortase A and GGGK-biotin (S, surface-displayed) or lysed and immunoprecipitated on immobilized HA beads (T, total). Uninfected cells
(lanes 1–3 and 4–6), IFN-I-treated cells in the presence or absence of Tsg101 (lanes 4–6 and 7–9), IFN-I-treated cytosol supplemented with Ubp43 in the presence
of Tsg101 (lanes 10–12), and the absence of Tsg101 (lanes 13–15). Autoradiograms are representative of at least three independent experiments.
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quantitation of total protein levels. First, we tested whether traf-
ficking characteristics of these reporters were altered upon IFN-I
induction. Intact MDCK cells expressing either CD40L or TfR
were exposed to IFN-I for 8 hr, radiolabeled, and chased for
various time intervals. Arrival at the cell surface was monitored
through sortase A-catalyzed biotinylation. We observed a clear
difference between transport characteristics of CD40L and TfR
to the cell surface upon IFN-I treatment. Arrival of CD40L at
the cell surface was abolished (Figure 6A), whereas that of TfR
was unaffected (Figure 6A) by IFN-I treatment. To confirm these
results, we measured the transport of TfR in permeabilized cells
supplemented with cytosol from control or IFN-I-treated cells
either proficient or deficient in Tsg101. Under all conditions,
TfR transport to the cell surface was unaffected (Figure 6B).
To explore whether the defect in CD40L transport upon IFN-I
treatment was also a Tsg101-dependent process, we tested
whether the trafficking of CD40L was altered by virus infection.
Transport of CD40L to the cell surface was monitored in IAV-
infected samples and in mock-infected controls (Figure 6C).
For both samples, cells were radiolabeled, permeabilized, and
incubated with exogenous MDCK cytosol containing Tsg101 or
immunodepleted of Tsg101. At 45 and 90 min, pellet fractionsCell Host &were collected, and the surface-disposed pool of CD40L was
modified by sortase A-catalyzed biotinylation followed by immu-
noprecipitation on NeutrAvidin beads. Because the LPETG tag is
lumenally oriented, it remains protected from sortase A unless
exposed at the cell surface. Transport of CD40L to the surface
and subsequent biotinylation was not affected in mock-infected
control cells irrespective of Tsg101 status. However, surface
exposure of CD40L in cells infected with IAV required Tsg101
(Figure 6C, top). Expression levels of CD40L remained constant
for all samples (Figure 6C, bottom). We conclude that post-Golgi
protein transport to the cell surface of CD40L becomes Tsg101-
dependent during IAV infection.
Next, we tested whether the alteration of CD40L trafficking
patterns was the result of an antiviral response that ensues
upon virus infection. We used MDCK cells that stably express
CD40L and radiolabeled them in a 15 min pulse. We permeabi-
lized these cells and incubated them with cytosol from IFN-
I-treated cells either Tsg101 replete or immunodepleted with
anti-Tsg101 antibodies. At 30 and 60 min, pellet fractions were
collected, and the surface-disposed fraction of CD40L was
modified by sortase A-catalyzed biotinylation as described.
Samples incubated with untreated MDCK cytosol supported
CD40L transport and biotinylation at the cell surface (Figure 6D,Microbe 14, 510–521, November 13, 2013 ª2013 Elsevier Inc. 517
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IFN-I-treated cytosol, transport of CD40L to the cell surface
was compromised irrespective of the presence of Tsg101.
Thus, results with CD40L recapitulate the characteristics of HA
transport under IFN-I treatment, and CD40L presumably suffers
a similar ISG15-imposed arrest. To relieve ISG15-mediated
inhibition of transport, we prepared cytosol from IFN-I-treated
cells and mixed it with Ubp43-containing cytosol (as described
above) followed by immunodepletion of Tsg101. In cells that
were incubated with cytosol from IFN-I-exposed cells supple-
mented with Ubp43, transport of CD40L to the cell surface
was restored in the presence of Tsg101. Cytosol depleted of
Tsg101 failed to support the appearance of CD40L at the cell
surface. Total levels of CD40L remained constant, as detected
by immunoprecipitation via the HA epitope (Figure 6D, bottom).
We conclude that, upon treatment with IFN-I, CD40L trafficking
patterns are altered such that they become dependent on
Tsg101 and sensitive to ISGylation, whereas patterns of CD71
remain unaffected because of distinct routes of transport.
DISCUSSION
Cells exploit twomajor trafficking pathways for the internalization
and export of cargo—the endocytic and the secretory pathways,
respectively. Proteins destined for the extracellular environment
enter the secretory pathway, mostly by cotranslational transloca-
tion into the ER and subsequent vesicular transport to the Golgi
and, finally, to the cell surface. However, during viral or bacterial
infections resulting in IFN induction, intracellular host protein
trafficking routes must necessarily be altered in order to regulate
cytokine secretion and the transport of other host proteins. Viral
glycoproteins most likely possess intrinsic determinants for
selecting sites of assembly, transport routes, and budding
(Rossman and Lamb, 2011; Schmitt and Lamb, 2005). Among
other host proteins typically involved in viral assembly, the family
of proteins of the ESCRT machinery interact with the Gag and
matrix proteins of a number of viruses, such as HIV and Ebola
(Martin-Serrano et al., 2001; Jouvenet et al., 2011; Freed, 2004).
These proteins include Tsg101 and those of the Nedd4 ligase
family (Okumura et al., 2008). Tsg101 functions in the ESCRT-I
complex as part of the vacuolar sortingmachinery, where it helps
select cargo for incorporation into vesicles that bud into multive-
sicular bodies (MVBs) (Razi and Futter, 2006). This process re-
quires the formation of vesicles that bud away from the cytosol
into the topological equivalent of extracellular space, a process
essentially similar to virus budding at the PM (Hanson and Cash-
ikar, 2012). Tsg101 is homologous to a ubiquitin E2-conjugating
enzyme but lacks the ability to engage in ubiquitin transfer,
notwithstanding its ability to interact tightly with ubiquitin.
Influenza viruses exit from discrete sites at the PM (Popp et al.,
2012; Rossman and Lamb, 2011) enriched in cholesterol and
sphingolipids. HA is the most abundant of the three envelope
proteins, and critical determinants for lipid association are
contained in its transmembrane domain (Ruigrok et al., 2000;
Tafesse et al., 2013; Tsurudome et al., 1992). Because a mutant
version of the AAA ATPase Vps4 devoid of enzymatic activity
does not inhibit IAV release, the involvement of the ESCRT com-
plex in IAV budding was considered unlikely (Bruce et al., 2009;
Watanabe and Lamb, 2010). In addition, M2 alters membrane518 Cell Host & Microbe 14, 510–521, November 13, 2013 ª2013 Elscurvature in vitro, suggesting that the final step of membrane
scission can be executedwithout the involvement of Vps4 (Ross-
man et al., 2010). Both intracellular transport and surface
display of HA, as reconstituted here in semi-intact cells, support
the lack of involvement of Vps4 in intracellular trafficking of HA or
release of virus. In contrast, the depletion of Tsg101 abolishes
HA transport to the cell surface and the subsequent release of
virus. In the semi-intact cell system, Tsg101-deficient cytosol
is added to infected, but otherwise normal, cells. Therefore,
there is no reason to assume that the secretory pathway in these
cells ismassively defective, an argument supported by the ability
to transport HA and allow the release of virus particles. Indeed,
the provision of control cytosol is required to have transport pro-
ceed, whereas Tsg101-depleted cytosol is ineffective. Although
the final stages of virus budding may indeed depend on M2,
Tsg101 appears to play a critical role in the recruitment of HA
to the cell surface prior to the release of IAV. Our demonstration
that Tsg101 is itself ISGylated in IFN-treated cells provides a
conceptual link between Tsg101’s ability to orchestrate mem-
brane trafficking and the consequences of IFN-I treatment on
the intracellular movement of glycoproteins. Transport of an en-
gineered CD40L shows a remarkable similarity to that of IAV HA,
whereas an unrelated type II membrane protein (TfR) appears
to follow a distinct trafficking route. The Tsg101-mediated
mode of transport is either not active or redundant under normal
physiological conditions, as confirmed by depletion from regular
cytosol with no inhibitory effect onCD40L transport. The features
of structure that confer this regulatory property on membrane
proteins remain to be determined but do not easily segregate ac-
cording to their type I or II transmembrane topology. We specu-
late that this property might extend to secreted proteins as well.
Accordingly we propose that factors induced by IFN-I treatment
differentially affect aspects of the secretory pathway, the details
of which remain to be determined.
The M1 protein encoded by influenza A virus contains a puta-
tive late domain motif (YKRL) and interacts with the N-terminal
ubiquitin E2 variant domain of Tsg101 (Diaz et al., 2009). M1
could facilitate influenza budding similar to the well-established
interaction of HIV Gag or Ebola VP-40 with Tsg101. Virus infec-
tion of host cells elicits the production of IFN and presumably
also attenuates or alters secretory activity. We speculate that
transport vesicles are generated in a Tsg101-dependent fashion
from the Golgi network, whereas the induction of IFN-I affects
such trafficking (Figure 7). ISGylation of Tsg101, and possibly
other components of the ESCRT machinery, would interfere
with the normal operation of at least some of these transport
pathways. The trafficking characteristics of CD40L and TfR
upon IFN-I induction might depend on features of their trans-
membrane segments, requiring specific lipid-protein interac-
tions, as observed for influenza HA and sphingomyelin (Tafesse
et al., 2013). These transport vesicles may be akin to sorting
endosomes or the ESCRT-dependent MVBs typically generated
from late endosomes—a multisubunit complex with several
components modified by ISG15. Hijacking of these transport
vesicles by IAV with its glycoproteins anchored to the limiting
membrane would allow arrival at the PM followed by M2-medi-
ated budding. The operation of this trafficking route is partially
supported by the finding that Rab11—a protein enriched in the
TGN and recycling endosomes and MVBs—is required for IAVevier Inc.
Figure 7. Proposed Model for Intracellular
Influenza Trafficking and Budding
Proteins destined for the cell surface are synthe-
sized at ER-bound ribosomes and traffic through
the secretory pathway to arrive at the extracellular
space. Influenza virus infection results in the in-
duction of IFNa and IFNb, which, in turn, create an
antiviral state in the host cell by regulating gene
expression and protein translation. Tsg101 func-
tions as part of the ESCRT complex to form mul-
tivesicular bodies; the induction of IFNs activates
an ISG15-regulated, Tsg101-dependent pathway
for rerouting proteins to the plasma membrane.
This pathway is exploited by influenza glycopro-
teins along with other membrane proteins, such as
CD40L, to traffic to the PM upon IFN induction.
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Our results predict that IAVmust be able to either exploit host de-
ISGylases or employ NS1 in order to prevent ISG15 levels from
reaching a threshold to be able to overcome the inhibition
imposed by IFN induction. Future work will determine whether
or not that occurs.
EXPERIMENTAL PROCEDURES
Antibodies, Cell Lines, and Constructs
MDCK, Vero, A549, and HEK 293T cells were purchased from American
Type Culture Collection and cultured. Serum containing IgG against A/
WSN/33 influenza HA was from a transnuclear mouse generated in the lab-
oratory. The antibody against the HA epitope was purchased from Roche
(3F-10). Plasmid encoding PFO was provided by A. Johnson (Texas A&M
University). Antibodies against Tsg101, Vps4, and IAV M1 were purchased
from Abcam. GTPgS was purchased from Sigma-Aldrich. The construct for
recombinant PFO and its purification have been described before (Sanyal
et al., 2012; Flanagan et al., 2009). HA agarose beads were purchased
from Roche, and protein A agarose beads were from RepliGen Bio-
processing. The generation of HA-Srt virus has been described before
(Popp et al., 2012).
HA-Transport Assays and Virus Budding in PFO-Permeabilized Cells
MDCK cells were grown to 80%–90% confluency, infected with WSN/33/A
virus for 5 hr, and labeled with [35S]cysteine/methionine at 37C in suspen-
sion. Labeled cells were treated with 0.1 mM PFO (in Hank’s balanced salt
solution [HBSS]) on ice as described above. Excess PFO was removed
by dilution in HBSS and centrifugation. For measuring IAV trafficking
and budding, 2.5 3 106 PFO treated semi-intact cells were incubated
with 100 mg of concentrated MDCK cytosol in 50 ml and incubated at
37C for 30 and 60 min. For all samples, cytosol preps used were normalizedCell Host & Microbe 14, 510–521, Nto total protein concentrations. At each time
point, cell suspensions were centrifuged at
1,000 3 g for 3 min in order to separate the pellet
and supernatant fractions. The pellets were
washed once with cold PBS and lysed (0.5%
NP-40, 150 mM NaCl, 5 mM MgCl2, and 25 mM
Tris [pH 7.5]). The supernatants were diluted to
500 ml in PBS, centrifuged further at 2,000 rpm
for 5 min in order to remove any contaminants,
and treated with chicken erythrocytes in order
to isolate released virus particles. HA was
recovered with serum from transnuclear mouse
immobilized on protein G sepharose beads.
Immunoprecipitated material was resolved by
SDS-PAGE and visualized by autoradiography.Chicken erythrocytes with adsorbed virions were lysed in resolving sample
buffer and loaded directly for SDS-PAGE.
Designing CRISPR Target Sequence and Prediction of Potential
Off-Target Effects
Potential target sequences for CRISPR interference were found with the
rules outlined in Mali et al. (2013). The seed sequence preceding the PAM
motif was found in the exon of Tsg101 as follows:Tsg101 target sequence,
CTGTTCTGTTTTCAGGCCGAGG. Potential off-target effects of the seed
sequence were confirmed with the NCBI Homo sapiens Nucleotide BLAST.
Procedure for Generating CRISPR RNA-Expressing Vector
The sense and antisense oligos were designed to incorporate into the restric-
tion enzymatic site BbsI of pX330 bicistronic expression vector expressing
Cas9 and synthetic single-guide RNA (Cong et al., 2013) as follows: sense
oligo, caccgCTGTTCTGTTTTCAGGCCG; antisense oligo, aaacCGGCCTGA
AAACAGAACAGc. The oligo DNAs were annealed, phosphorylated, and
incorporated into pX330 vector linearized with BbsI restriction enzyme.
Limiting Dilution to Generate Tsg101 Knockout Cell Lines
A549 cells were transfected with the Tsg101-targeting pX330 with FuGENE6
reagent (Promega) according to the manufacturer’s instructions. The cells
were replated 12 hr after transfection to a 96-well plate at a density of 0.5 cells
per well. The individual colonies were picked, and the expressions of Tsg101
were checked by immunoblotting.
Plaque Assay
Serial dilutions of supernatants from infected cells were overlaid on MDCK
cells and incubated for 30 min. Cells were washed, and plaque media was
added to the cells (MEM; 0.8% agar, 1 mg/ml trypsin) and placed at 37C. Cells
were fixed in 4% paraformaldehyde 48 hr after infections, and the agar plug
was removed. Cells were blocked in 5% BSA and 1% goat serum and probed
with anti-NP VHH54-biotin followed by streptavidin-HRP (GE Healthcare,ovember 13, 2013 ª2013 Elsevier Inc. 519
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Substrate (Kirkegaard and Perry Laboratories, 50-78-02).
Immunodepletions of Tsg101 and Vps4
100 ml of concentrated cytosol from MDCK cells (500 mg protein) isolated
by PFO treatments was subjected to control beads and anti-Vps4 or anti-
Tsg101 immobilized on protein A sepharose beads. After incubation for 3 hr
at 4C, flowthrough fractions were collected from mock-depleted, Vps4-defi-
cient, or Tsg101-deficient samples and subjected to immunoblotting in order
to confirm depletion. GAPDH was used as a loading control in order to verify
that depletion was specific. Immunodepleted cytosol was incubated with
semi-intact cells in order to measure HA transport and virus budding as
described before.
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